ArticleAdvanced pharmaceutical bulletin2023

Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism.

Konstantinos Papadopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.